4 hours ago
1
jetcityimage/iStock Editorial via Getty Images
- Eli Lilly (NYSE:LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) approved a label update for its Alzheimer’s therapy Kisunla (donanemab-azbt) to allow for a new titration dosing schedule.
- The once-monthly antibody therapy, approved by the FDA in
English (US) ·